RTTNews | May 18, 2021 10:24AM EDT

10:23 Tuesday, May 18, 2021 (RTTNews.com) - Shares of Sarepta Therapeutics, Inc. (SRPT) are currently gaining about 10% after the company announced positive results from a study of investigational treatment for a rare muscle disorder.

SRPT is currently trading at $82.18, up $7.06 or 9.39%, on the Nasdaq.

Sarepta Therapeutics announced positive 12-week expression and safety results from the first 11 participants enrolled in Study SRP-9001-103, an open-label study known as ENDEAVOR being conducted in partnership with Roche.

Sarepta said it investigational gene therapy for the treatment of duchenne muscular dystrophy, SRP-9001, demonstrated robust expression and consistent safety profile using the company's commercial process material.

SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.

Read the original article on RTTNews ( https://www.rttnews.com/3195769/stock-alert-sarepta-therapeutics-up-9.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved